Cancer ImagingPub Date : 2026-10-24DOI: 10.1186/s40644-026-01134-5
Julius C Holzschuh, Lukas T Rotkopf, Christian Neelsen, Fabian Bauer, Kevin S Zhang, Ekaterina Menis, Marina Hajiyianni, Elias Karl Mai, Niels Weinhold, Lukas John, Christos Sachpekidis, Antonia Dimitrakopoulou-Strauss, Marc-Steffen Raab, Hartmut Goldschmidt, Johann Jende, Stefan Delorme, Heinz-Peter Schlemmer, Markus Wennmann
{"title":"AI-based automated body composition analysis from whole-body MRI and (PET-) CT: an intermodal comparison from same-day examinations.","authors":"Julius C Holzschuh, Lukas T Rotkopf, Christian Neelsen, Fabian Bauer, Kevin S Zhang, Ekaterina Menis, Marina Hajiyianni, Elias Karl Mai, Niels Weinhold, Lukas John, Christos Sachpekidis, Antonia Dimitrakopoulou-Strauss, Marc-Steffen Raab, Hartmut Goldschmidt, Johann Jende, Stefan Delorme, Heinz-Peter Schlemmer, Markus Wennmann","doi":"10.1186/s40644-026-01134-5","DOIUrl":"10.1186/s40644-026-01134-5","url":null,"abstract":"<p><strong>Background: </strong>To determine intermodal agreement of AI-derived volumetric body composition metrics between [18 F]FDG-PET/CT-derived low-dose CT and whole-body MRI (wb-MRI).</p><p><strong>Methods: </strong>We retrospectively analyzed same-day whole-body low-dose CT, obtained from [<sup>18</sup>F]FDG-PET/CT, and wb-MRI from consecutive multiple myeloma patients from the prospective GMMG-HD7- and GMMG-HD8-/DSMM-XIX-trials. An automated deep learning pipeline based on the TotalSegmentator model, and its MRI variant were used to segment skeletal muscle (SM), subcutaneous- (SAT) and abdominal visceral adipose tissue (VAT) from CT and MRI, respectively. Volumetric measures and single-slice estimates were derived. Agreement between CT- and MRI-based metrics was assessed using Pearson r, intraclass correlation coefficients (ICC), and Bland-Altman analyses.</p><p><strong>Results: </strong>Forty-two multiple myeloma patients with same-day PET/CT and wb-MRI were included. For AI-based volumetric body composition metrics, CT and MRI demonstrated high agreement (ICC > 0.95) across all SM, SAT and VAT. However, Bland-Altmann plots revealed systematic modality-related differences between MRI and CT: both SM (bias: -2582 ml, p < 0.0001) and VAT (bias: -211 ml, p < 0.0001) were significantly lower when extracted from MRI compared to CT, while for SAT, the difference was not statistically significant (bias: -263 ml, p = 0.1629). For AI-based single slice analysis, agreement remained high for SAT and VAT (ICC > 0.97), while being lower for SM (ICC 0.87). Bland-Altman plots showed that SM was systematically and significantly lower when obtained from MRI than from CT (bias: -18.4cm<sup>2</sup>, p < 0.0001).</p><p><strong>Conclusions: </strong>Automated body composition measures from (PET-)CT and wb-MRI are highly concordant but show consistent intermodal biases that should be considered when pooling multimodal data or applying modality-agnostic thresholds.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"26 1","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13700498/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149262991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer ImagingPub Date : 2026-10-21DOI: 10.1186/s40644-026-01140-7
Milena Petranović, Ashley E Prosper, Andetta R Hunsaker, Stephen Lam, Jared D Christensen
{"title":"ACR lung-RADS: updates and future directions.","authors":"Milena Petranović, Ashley E Prosper, Andetta R Hunsaker, Stephen Lam, Jared D Christensen","doi":"10.1186/s40644-026-01140-7","DOIUrl":"10.1186/s40644-026-01140-7","url":null,"abstract":"<p><p>Lung cancer remains the leading cause of cancer-related mortality worldwide, and low-dose CT (LDCT) screening has been shown to significantly reduce lung cancer deaths in high-risk populations. The American College of Radiology (ACR) introduced the Lung CT Screening Reporting and Data System (Lung-RADS) in 2014 to standardize the reporting and management of screen-detected pulmonary nodules. Since its inception, Lung-RADS has undergone iterative updates reflecting advances in evidence, clinical practice, and the expanding scope of lung cancer screening. This review summarizes the major updates to Lung-RADS, highlights areas of active discussion within the Lung-RADS Committee, and outlines future research directions. Key topics include the ongoing evaluation of volumetric versus diameter-based nodule measurement, the management of subsolid nodules and the balance between surveillance and intervention, the implementation of Category 0 for infectious or inflammatory findings, clarification of juxtapleural nodule classification, the approach to incidental findings, and the development of a Lung-RADS Atlas. Future directions address the integration of risk-based and category-based assessment approaches, the role of artificial intelligence and deep learning in nodule stratification, the potential incorporation of incidental nodules into Lung-RADS, and the prospect of international harmonization for lung cancer screening reporting and management. Lung-RADS has become an essential reporting and quality tool for lung cancer screening in the United States and increasingly worldwide. Continued refinement, guided by emerging evidence, multidisciplinary collaboration, and technological innovation, will be critical to advancing precision screening strategies and reducing the global burden of lung cancer.Clinical trial numberNot applicable.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"26 1","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149237068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer ImagingPub Date : 2026-10-21DOI: 10.1186/s40644-026-01146-1
Ehsan Khodamoradi
{"title":"Misreporting of study design and validation status in a study of early tumour shrinkage in esophageal squamous cell carcinoma.","authors":"Ehsan Khodamoradi","doi":"10.1186/s40644-026-01146-1","DOIUrl":"10.1186/s40644-026-01146-1","url":null,"abstract":"<p><p>This letter to the Editor addresses a fundamental inconsistency in the reporting of study design and validation status in the article by Zhou et al. published in Cancer Imaging. The authors state in the Methods section that the study retrospectively analyzed 125 patients, yet the Introduction and Discussion claim that the study prospectively validated the prognostic value of early tumour shrinkage (ETS) and depth of response (DoR). Prospective validation requires a priori model specification and evaluation on subsequently collected data, whereas retrospective analyses are inherently susceptible to selection bias and cannot establish prospective validity. The authors also conclude that they developed and validated a comprehensive predictive model, but no external validation, temporal validation, or clearly described internal validation procedure is reported. The ETS and DoR thresholds were derived from ROC analysis within the same cohort and then applied to the same patients for survival analysis, risking overfitting and optimistic bias. Additionally, the Results report \"responders (n = 109) and non-responders (n = 12),\" while the corresponding results in the original article by Zhou et al. [1] list the ratio as 12/109, reversing the group labels. We respectfully suggest that the authors clarify the actual study design, remove any claim of prospective validation if the study is retrospective, provide evidence of validation or remove the claim of a validated model, and correct the numerical inconsistency. Such corrections would uphold the scientific integrity of the literature.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"26 1","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149237078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer ImagingPub Date : 2026-10-21DOI: 10.1186/s40644-026-01138-1
Matthijs Oudkerk
{"title":"Tumor growth rate as a new imaging biomarker in early detection of lung cancer.","authors":"Matthijs Oudkerk","doi":"10.1186/s40644-026-01138-1","DOIUrl":"10.1186/s40644-026-01138-1","url":null,"abstract":"","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"26 1","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149237021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer ImagingPub Date : 2026-10-08DOI: 10.1186/s40644-026-01137-2
Felix Busch, Alexander W Marka, Lilly F Wingberg, Philipp Prucker, Su Hwan Kim, Quirin Strotzer, Christina Schmidt, Jacqueline Lammert, Kai J Borm, Jan Peeken, Marcus R Makowski, Lisa C Adams, Keno K Bressem
{"title":"Multidisciplinary attitudes towards LLM-structured oncologic CT reports: a prospective fixed-sequence questionnaire study.","authors":"Felix Busch, Alexander W Marka, Lilly F Wingberg, Philipp Prucker, Su Hwan Kim, Quirin Strotzer, Christina Schmidt, Jacqueline Lammert, Kai J Borm, Jan Peeken, Marcus R Makowski, Lisa C Adams, Keno K Bressem","doi":"10.1186/s40644-026-01137-2","DOIUrl":"10.1186/s40644-026-01137-2","url":null,"abstract":"<p><strong>Objectives: </strong>Large language models (LLMs) can automate the conversion of radiologic free text into structured reports, but multidisciplinary reader preferences for the resulting output remain insufficiently studied. This prospective, two-phase, fixed-sequence within-participant study evaluated reader assessments of LLM-structured versus conventional free-text oncologic CT reports.</p><p><strong>Material & methods: </strong>A paired convenience sample of radiologists, radiology technologists, oncologists, and medical students was recruited between May and November 2025. In Phase 1, participants rated 5 free-text oncologic CT reports for readability and comprehension (3 items), oncologic information quality (5 items), and clinical utility (4 items) on a 9-point Likert scale. After a washout of at least 4 weeks, participants rated the LLM-structured version generated by Llama-4-Scout-17B-16E-Instruct.</p><p><strong>Results: </strong>Sixty-six paired participants (24 medical students, 22 radiologists, 12 radiology technologists, 8 oncologists) were included (mean [standard deviation] age, 30.5 [7.6] years; 37 [56.1%] female). Structured reports showed significantly higher odds of agreement for 11 of 12 items (odds ratio [OR] range, 1.70-4.81), with strongest effects for clinical utility (OR, 4.81; 95% CI, 3.24-7.15), information findability (OR, 4.31; 95% CI, 3.12-5.96), recommendation clarity (OR, 4.14; 95% CI, 2.95-5.83), and patient communication suitability (OR, 3.45; 95% CI, 2.59-4.60). Radiology technologists showed significantly higher ratings for all 12 items, radiologists for 6, students for 7, and oncologists for none.</p><p><strong>Conclusion: </strong>In this single-center paired sample, LLM-structured oncologic CT reports received higher reader ratings than conventional free-text reports across most evaluated dimensions, with the largest differences observed for information findability and clinical utility. These findings support further evaluation of radiologist-supervised LLM-assisted report structuring, including formal source-to-output validation and randomized multicenter assessment, before clinical implementation.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"26 1","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13651054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149134740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer ImagingPub Date : 2026-10-01DOI: 10.1186/s40644-026-01135-4
Seval Akbal, Johan Constantin Schepers, Paul V Op Gen Oorth, Vincent Bleymehl, Moritz Schroth, Felix Winneknecht, Devayani Machiraju, Julius C Holzschuh, Kevin S Zhang, Sebastian Wohlfeil, Isabelle Ayx, Stefan O Schoenberg, Heinz-Peter Schlemmer, Jessica C Hassel, Lukas T Rotkopf
{"title":"CT radiomics showed no improvement beyond volume dynamics for early lesion-level size response to immunotherapy in metastatic melanoma.","authors":"Seval Akbal, Johan Constantin Schepers, Paul V Op Gen Oorth, Vincent Bleymehl, Moritz Schroth, Felix Winneknecht, Devayani Machiraju, Julius C Holzschuh, Kevin S Zhang, Sebastian Wohlfeil, Isabelle Ayx, Stefan O Schoenberg, Heinz-Peter Schlemmer, Jessica C Hassel, Lukas T Rotkopf","doi":"10.1186/s40644-026-01135-4","DOIUrl":"https://doi.org/10.1186/s40644-026-01135-4","url":null,"abstract":"<p><strong>Background: </strong>We evaluated whether CT intensity and texture radiomics provide predictive value beyond simple volume dynamics for lesion-level response prediction in metastatic melanoma treated with immune checkpoint inhibitors.</p><p><strong>Methods: </strong>We conducted a retrospective multicenter study including 158 patients (1,626 lesions) from an internal cohort (n = 129 patients with standardized protocols) and an external cohort (n = 29 patients with heterogeneous protocols). The primary endpoint was binary lesion-level size response (clinical benefit vs. progressive disease) at the second follow-up. We trained and compared Random Forest classifiers to predict this endpoint using clinical variables, volumetric features, radiomics, and combined predictors derived from baseline and first follow-up imaging. Models were trained on the internal cohort using patient-grouped cross-validation and applied unchanged to the external cohort. Paired differences in AUC were assessed against a ± 0.05 equivalence margin.</p><p><strong>Results: </strong>Baseline-only prediction of first follow-up response was near chance for all models. For predicting response at second follow-up, the volumetric model achieved an internal AUC of 0.84 [95% CI 0.78-0.88] and the radiomics model 0.86 [0.81-0.90]. In the external cohort, with 12 progression events, the volumetric and radiomics models achieved AUCs of 0.68 [0.50-0.85] and 0.68 [0.51-0.88], with no significant difference between any models. Organ-specific analysis showed no significant improvement from adding radiomics for any lesion site. Across all 288 radiomic features, the median absolute correlation with lesion volume was 0.37. Sensitivity analyses contained small or borderline gains that did not replicate externally.</p><p><strong>Conclusions: </strong>Volumetric features capture the primary predictive information for early lesion-level response, and CT radiomics showed no conclusive improvement over volume dynamics. Confirmation in larger independent cohorts is required before radiomic signatures can be recommended for this task.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"26 1","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13632448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer ImagingPub Date : 2026-09-18DOI: 10.1186/s40644-026-01094-w
{"title":"Proceedings of the 25th International Cancer Imaging Society Meeting and Annual Teaching Course.","authors":"","doi":"10.1186/s40644-026-01094-w","DOIUrl":"10.1186/s40644-026-01094-w","url":null,"abstract":"","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"26 Suppl 1","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13587269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148988259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer ImagingPub Date : 2026-09-15DOI: 10.1186/s40644-026-01126-5
Nadine Bayerl, Joel Appel, Maximilian Schmidt, Alexander Cavallaro, Robert Grimm, Heinrich von Busch, Bernd Wullich, Arndt Hartmann, Michael Schlicht, Michael Uder, Matthias S May, Stephan Ellmann
{"title":"Diagnostic performance of AI-powered prostate MRI against biopsy ground truth: quasi-continuous risk scoring versus fixed PI-RADS thresholds.","authors":"Nadine Bayerl, Joel Appel, Maximilian Schmidt, Alexander Cavallaro, Robert Grimm, Heinrich von Busch, Bernd Wullich, Arndt Hartmann, Michael Schlicht, Michael Uder, Matthias S May, Stephan Ellmann","doi":"10.1186/s40644-026-01126-5","DOIUrl":"10.1186/s40644-026-01126-5","url":null,"abstract":"<p><strong>Background: </strong>Multiparametric prostate MRI is central to prostate cancer (PCa) diagnostics, yet PI-RADS interpretation suffers from inter-reader variability. This study aimed to evaluate a commercial AI algorithm for cancer detection in prostate MRI against histopathology, comparing its standard PI-RADS classification with its quasi-continuous Level-of-Suspicion (LoS) score as decision variables.</p><p><strong>Methods: </strong>In this retrospective single-center study, 122 mpMRI examinations, each followed by systematic and/or fusion-targeted biopsy, were analyzed. Histopathology served as the reference standard for any PCa (Gleason ≥ 6) and clinically significant PCa (csPCa; Gleason ≥ 7). Diagnostic performance of the algorithm's PI-RADS and LoS outputs was assessed by ROC analysis. AUCs were compared using DeLong's test. The Youden-optimal LoS cutoff was determined, its optimism was quantified by bootstrap internal validation, and the calibration of the LoS score was assessed after logistic recalibration.</p><p><strong>Results: </strong>For csPCa, PI-RADS yielded an AUC of 0.833 (95% CI: 0.764-0.901), versus 0.882 (95% CI: 0.820-0.943) for the LoS score (p = 0.106). At PI-RADS ≥ 4, sensitivity was 94.7% and specificity 63.1%. The Youden-optimal LoS cutoff was 81. At this exploratory threshold, sensitivity remained 94.7% while specificity was 70.8%, with positive and negative predictive values of 74.0% and 93.9%, respectively. Bootstrap internal validation indicated modest optimism, with corrected estimates of 92.9% for sensitivity and 69.1% for specificity. After logistic recalibration, the bootstrap-corrected calibration slope was 0.98 with an intercept of -0.01.</p><p><strong>Conclusion: </strong>In this retrospective single-center cohort, the AI algorithm achieved high diagnostic accuracy for csPCa. Its quasi-continuous LoS score provided an operating point combining high sensitivity with numerically higher specificity than the PI-RADS ≥ 4 threshold. Neither this difference (exact McNemar p = 0.063) nor the difference in AUC between the two classifiers (p = 0.106) reached statistical significance, so the finding should be regarded as a promising trend rather than a demonstrated advantage. Prospective confirmation is required before AI-assisted standardized interpretation is integrated into prostate MRI workflows on this basis.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"26 1","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13580003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148975590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Quantitative PCCT spectral parameters for noninvasive prediction of EGFR status and its subtypes in lung adenocarcinoma.","authors":"Jiazhong Ren, Yong Huang, Linfeng Li, Yuqin Jin, Yong Yin","doi":"10.1186/s40644-026-01122-9","DOIUrl":"https://doi.org/10.1186/s40644-026-01122-9","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the non-invasive predictive value of quantitative spectral parameters from photon-counting computed tomography (PCCT) for epidermal growth factor receptor (EGFR) mutation status and its predominant subtypes (19Del and L858R) in patients with lung adenocarcinoma.</p><p><strong>Methods: </strong>A total of 72 patients with pathologically confirmed lung adenocarcinoma who underwent pretreatment PCCT were retrospectively enrolled. Arterial and venous CT attenuation values at 40 keV, 70 keV, and 100 keV (A/V-40 keV, A/V-70 keV, A/V-100 keV) were measured on virtual monoenergetic images, while arterial/venous iodine concentration (IC) and dual-energy index (DEI) of lesions were measured on iodine maps and spectral post-processing (SPP) images, respectively. Normalized iodine concentration (NIC) and spectral curve slope (λHU) were further calculated. Receiver operating characteristic (ROC) curve analysis and binary logistic regression were performed to evaluate the predictive performance and independent predictive value of PCCT parameters for discriminating EGFR-mutant vs. wild-type tumors, as well as 19Del vs. L858R subtypes.</p><p><strong>Results: </strong>Of 72 patients, 37 (51.4%) harbored EGFR mutations, which correlated with female sex, never-smoking, reduced NSE, and lower monocyte count. The EGFR-mutant group showed significantly higher A-70 keV, A-100 keV, A-DEI, V-40 keV, V-70 keV, V-100 keV, V-λHU and V-DEI (all P < 0.05). Logistic regression identified female sex (P = 0.019, OR = 5.714, 95% CI: 1.336-24.442) and A-100 keV (P = 0.044, OR = 0.543, 95% CI: 0.300-0.983) as independent predictors. ROC analysis with bootstrap validation yielded: clinical model AUC 0.767 (optimism-corrected 0.762); PCCT model AUC 0.713 (optimism-corrected 0.707); combined model AUC 0.771 (optimism-corrected 0.768) (all P < 0.001). Between 19Del (n = 15) and L858R (n = 17) subgroups, A-40 keV and A-DEI showed significant discriminative performance in ROC analysis, with AUCs of 0.694 and 0.704 (optimism-corrected AUCs: 0.688 and 0.697, respectively).</p><p><strong>Conclusions: </strong>Quantitative PCCT spectral parameters enable non-invasive prediction of EGFR mutation status and preliminary differentiation between 19Del and L858R subtypes in lung adenocarcinoma, though subtype-related findings require validation in larger cohorts. Female sex and A-100 keV are independent predictive factors. The combined model yielded a numerically higher AUC without statistically significant superiority, and PCCT parameters may provide auxiliary imaging evidence to inform individualized targeted therapy decisions in lung adenocarcinoma.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"26 1","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13625330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer ImagingPub Date : 2026-08-31DOI: 10.1186/s40644-026-01118-5
Jichen Yang, Li Ma, Xiaoming Zhao, Peng Jin, Xue Meng, Wenxing Du, Zhe Wu, Wenjie Jiao, Wenfeng Yang
{"title":"<sup>18</sup>F-FDG PET/CT metabolic parameter to predict pathological complete response and survival after neoadjuvant immunotherapy plus chemoradiotherapy in resectable esophageal squamous cell carcinoma.","authors":"Jichen Yang, Li Ma, Xiaoming Zhao, Peng Jin, Xue Meng, Wenxing Du, Zhe Wu, Wenjie Jiao, Wenfeng Yang","doi":"10.1186/s40644-026-01118-5","DOIUrl":"10.1186/s40644-026-01118-5","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant immunotherapy plus chemoradiotherapy (nICRT) for esophageal squamous cell carcinoma (ESCC) received increasing attention because of high pathological complete response (pCR) rate. Accurately assessing residual disease after nICRT is beneficial for dynamic monitoring of patients. This exploratory, single-arm, phase II clinical study aimed to evaluate the diagnostic efficacy of <sup>18</sup>F-FDG PET/CT for achieving pCR after nICRT for ESCC, and its prognostic value for survival.</p><p><strong>Methods: </strong>From January 12, 2021 to February 21, 2023, a total of 21 resectable ESCC patients receiving nICRT were enrolled and underwent baseline PET/CT scans (scan-1) and surgery. 19 patients underwent scans (scan-2) before surgery. The recorded PET/CT parameters included maximum, mean, and peak standardized uptake values (SUVmax, SUVmean, and SUVpeak), metabolic tumor volume (MTV), and total lesion glycolysis (TLG). The diagnostic performance of PET/CT parameters was analyzed between the patients with pCR of the primary tumor (pCR-tu) and non-pCR-tu. The Cox regression and Kaplan-Meier method were performed for multivariable analysis and survival analyses, respectively.</p><p><strong>Results: </strong>13(61.9%) achieved pCR-tu after nICRT among the 21 participants. None of the single metabolic parameters of primary tumor were significant predictors of pCR-tu (all p > 0.05). SUVmax2 of lymph nodes (Ln) has diagnostic value for lymph nodes metastasis (p < 0.01), the area under the curve (AUC), sensitivity and specificity were 0.812, 77.8% and 76.9%, respectively. The 3-year overall survival (OS) and disease-free survival (DFS) rates were 76.2% and 66.7%, respectively. Univariate Cox regression indicated that OS and DFS were correlated with the postoperative ypN stage, ypTNM stage, pCR, pCR-tu, SUVmax2, and LnSUVmax2. Long rank analysis showed that patients with a cutoff value of ≥12.4 for SUVmax2 and of ≥7.9 for LnSUVmax2 had poorer OS and DFS. However, multivariate Cox regression showed that the parameters mentioned above were not independent prognostic factors for OS and DFS.</p><p><strong>Conclusions: </strong>None of the single metabolic parameters of the primary tumor were significant predictors of pCR-tu. LnSUVmax2 has diagnostic value for lymph nodes metastasis. The patients with SUVmax2 ≥ 12.4 and LnSUVmax2 ≥ 7.9 had poorer OS and DFS, but they are not independent prognostic factors, which needs to be confirmed by larger scale clinical studies.</p><p><strong>Trial registration: </strong>NCT05323890. Registered on April 5, 2022. Retrospectively registered.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"26 1","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13584425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148988252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}